Summarized by Masters of Longevity from Longevity Docs News.
Open-label extension patients declined 2.05 CDR-SB points less than matched controls.

Key Takeaways
- Treated early Alzheimer’s patients showed 2.05 point less decline.
- The clinical gap continued to widen after 18 months.
- Findings were from company-reported open-label comparison without controls.



